Farshad Roghani - Associate Professor, Interventional Cardiologist, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, ‎Isfahan, Iran
Babak Shirani - Resident, Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Omid Hashemifard - Interventional Cardiologist, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical ‎Sciences, Isfahan, Iran

BACKGROUND: The potential risk of vascular complications associated with heparin, the dose of heparin therapy has not been exactly examined in patients undergoing transradial angiography. Thus, this study was aimed to compare referral arterial thrombosis, hematoma and hemorrhagic complications with ۲۵۰۰ and ۵۰۰۰ IU arterial heparin and the association of these complications with predictors in patients undergoing diagnostic angiography. METHODS: This prospective, randomized, double-blind controlled trial was carried out on ۴۴۱ patients aged ≥ ۱۸-year-old in Isfahan, Iran. They were referred for diagnostic coronary angiography with radial access. First participants were randomized into to inject either ۲۵۰۰ IU (group A) or ۵۰۰۰ IU (group B) of heparin. Study’s primary endpoints were thrombosis, hematoma, and hemorrhage. RESULTS: The frequency of thrombosis was ۲۵.۵% in group A vs. ۲.۳% in group B (P < ۰.۰۰۱), while the frequency of hematoma had no significant differences in group A and B. None of patients in both groups had hemorrhage. Using ۵۰۰۰ IU of heparin protected the occurrence of thrombosis by ۹۵% [odds ratio (OR): ۰.۰۵, ۹۵% confidence interval (CI): ۰.۰۲-۰۱۲] after adjustment for confounders. CONCLUSION: The low dose (۲۵۰۰ IU) versus standard dose (۵۰۰۰ IU) of heparin use increased the risk of thrombosis following trans-radial diagnostic coronary angiography, with no effect on hematoma and bleeding.

Coronary Angiography, Thrombosis, Hemorrhage, Hematoma